<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629733</url>
  </required_header>
  <id_info>
    <org_study_id>ROV-RO14-2006-01</org_study_id>
    <nct_id>NCT00629733</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rovi Pharmaceuticals Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rovi Pharmaceuticals Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular
      weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male
      volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main objective : To evaluate safety and tolerability of increasing single-doses to healthy male volunteers</measure>
    <time_frame>safety parameters</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives : To evaluate pharmacokinetics profiles of each of single-doses.</measure>
    <time_frame>anti-Xa activity</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ro-14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO-14</intervention_name>
    <arm_group_label>Ro-14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers: male subjects aged between 18 and 45 years

          2. Body weight: 65-75 Kg

          3. Not meaningful abnormalities in physical examination and in clinical history

          4. Without evidence of significant organic or psychiatric illness

          5. Hemogram, biochemistry and coagulation in normal values established in the reference
             range of the local hospital laboratory

          6. Vital signs (blood pressure, heart beat rate and body temperature) and EKG within
             normal range

          7. Healthy volunteers who are not participating in another clinical trial or have not
             done so in the past 2 months

          8. Not give blood in the last 4 weeks.

          9. Healthy male volunteers who have not received heparin in the past

         10. Healthy male volunteers who have accepted to participate in the study and have signed
             the written informed consent

        Exclusion Criteria:

          1. Previous history of alcoholism, drug dependency, drug abuse or habitual psychoactive
             drugs consumption

          2. Important consumption of exciting drinks: alcohol consumption &gt; 30 g/day; coffee, tea,
             cola &gt; 5 /day

          3. Allergy, idiosyncrasy or hypersensitivity to medicines

          4. Healthy volunteers who are receiving another medication in the past 15 days

          5. Positive serology of hepatitis B, C or HIV

          6. Cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematologic,
             psychiatric, neurological and others events

          7. Mayor Surgery in the last 6 months

          8. Smoking &gt; 10 cigarettes / day

          9. Ethanol, cannabis, cocaine, amphetamine, benzodiazepine or opiate in urine

         10. Healthy volunteers with a familiar history evident hemorrhagic episodes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Manuel Barbanoj</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Barbanoj</name_title>
    <organization>Hospital Santa Creu i Sant Pau</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>ultra low molecular weight heparin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

